Pipeline Review of Global Tuberculosis Drugs Market: Overview
Tuberculosis, mainly referred to as TB, is caused by bacterium Mycobacterium tuberculosis. It is a contagious, airborne malady that occurs mostly in lungs but can spread through the lymph nodes and bloodstream to other organs in the lymphatic system, central nervous system, and circulatory system among others. Most people who carry the bacteria, however, do not exhibit any external symptoms. This condition is known as latent TB. The immune system puts up a strong resistance and thus prevents the person carrying the germ from falling ill on account of it.
Latent TB can develop into an active one and show symptoms such as cough, which is sometimes accompanied by bloody mucus, shortness of breath, fatigue, fever, weight loss, and chest pain. Once active, the respiratory disease becomes contagious. It can then be transmitted from one person to another through droplets from the lungs and throat. Tuberculosis can be cured with a six-months antibiotics course.
The research report has been compiled leveraging primary and secondary research methodologies to present an accurate analysis of the global tuberculosis drugs in the offing. It furnishes a description of the product and discusses the research and development methodology, the licensing process, latest news surrounding them, deals and collaborations, and other details pertaining to their developmental processes. It outlines all the dormant and discontinued pipeline projects. The report reviews key players involved in the development of tuberculosis drugs and throws light on their major and minor projects.
Pipeline Review of Global Tuberculosis Drugs Market: Drivers and Trends
According to the World Health Organization (WHO), TB was one of the top 10 causes of death worldwide in 2015. It claimed an estimated 1.8 mn lives in 2015, which was more than that claimed by HIV and malaria. Globally, 10.4 mn people got afflicted by TB in 2015. This has led to increased emphasis on developing new and more effective drugs. The research finds that active tuberculosis, if it's a drug-resistant strain especially, will need several drugs simultaneously.
The rise of multidrug-resistant TB (MDR-TB) and extensive drug-resistant TB (XDR-TB) strains alongside growth in the number of other mutant and antibiotic-resistant TB strains is driving growth in the global tuberculosis drugs market. Some of the common medicines that find application in treating tuberculosis are Rifampin (Rifadin, Rimactane), Ethambutol, Isoniazid, and Pyrazinamide. The report offers information on the latest developments in the tuberculosis drug-development pipeline, including new antimicrobials and host-directed drugs that are meant to have better outcomes. It states that some the new or repurposed antimicrobial drugs are in advanced trial stages for multi-drug resistant (MDR) tuberculosis, and two new antimicrobial drugs are in the early-stages of trials. Several trials to reduce the time taken for the therapy in MDR and drug-susceptible tuberculosis are underway now.
A robust pipeline of new vaccines has come up in the last few years with almost 15 TB vaccines entering clinical trials. Companies are more focused on developing effective vaccines against the spread of the TB infection. At present, Bacille Calmette-Guerin (BCG) vaccine is the sole vaccine for tuberculosis and it is not very active in protecting against the adolescent or adult form of tuberculosis, particularly lung or pulmonary tuberculosis.
Pipeline Review of Global Tuberculosis Drugs Market: Geographical Outlook
The report segments the tuberculosis drugs market geographically into Europe, North America, Asia Pacific, and the Rest of the World. It finds that in emerging economies, there is heightened focus on bettering vaccine production capacity to meet the needs of the patients. Among the emerging economies, the Indian market for tuberculosis drugs is a dominant one. Rifampicin-based products is particularly popular in the country, along with fixed-dose combinations (FDCs). However, nations that register maximum cases of tuberculosis, such as Brazil, China, India, Indonesia, Russia, and South Africa, need to attach more importance to research and development.
Key Players Mentioned in the Report
The review of therapeutic development for tuberculosis drugs market analysis provides a peek into the competitive landscape, by studying the leading industry players by factoring in their products in the pipeline, capacity, cost of development. Some such players are GlaxoSmithKline, AVI BioPharma, Eli Lilly and Company, Johnson & Johnson, Vertex Pharmaceuticals, AstraZeneca, ISA Pharmaceuticals, and Chimerix.
Major geographies analyzed under this research report are:
- North America
- Asia Pacific
- Rest of the World (RoW)
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report:
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.